Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

3(50.0%)

6Total

Phase 1(3)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03870334Phase 2Terminated

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Role: lead

NCT03861143Phase 2Completed

Efficacy and Safety of Oral BT-11 in Ulcerative Colitis

Role: lead

NCT05019950Phase 1Completed

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

Role: lead

NCT03860571Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Role: lead

NCT05057273Phase 2Withdrawn

Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

Role: lead

NCT04835168Phase 1Withdrawn

Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

Role: lead

All 6 trials loaded